# Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

> **NCT05717153** · EARLY_PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 18 (estimated)

## Conditions studied

- Diffuse Glioma
- Malignant Glioma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Eflornithine
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Polyamine Transport Inhibitor AMXT-1501 Dicaprate
- **PROCEDURE:** Resection
- **DEVICE:** Microdialysis
- **PROCEDURE:** Placement

## Key facts

- **NCT ID:** NCT05717153
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-09-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05717153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05717153, "Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05717153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*